Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
A new study finds relapse within 12 months (TTR12) strongly predicts poor survival in aggressive T-cell lymphoma, helping doctors identify high-risk patients earlier.
A new study led by MIT and Massachusetts General Hospital identifies TTR12—relapse within 12 months of treatment—as a powerful predictor of poor survival in aggressive nodal mature T-cell lymphoma, a rare and deadly blood cancer.
Using a causal inference method called Synthetic Survival Controls, researchers found the marker predicts outcomes regardless of treatment type or existing risk scores.
The tool enables "when-if" analyses to estimate how survival might change under different therapies, helping clinicians identify high-risk patients earlier and consider targeted treatments or clinical trials sooner.
The approach, developed by MIT graduate student Jessy Han, could improve personalized care and is applicable beyond oncology.
Findings were published in Blood.
Un nuevo estudio encuentra que la recaída dentro de los 12 meses (TTR12) predice fuertemente una pobre supervivencia en el linfoma agresivo de células T, ayudando a los médicos a identificar a los pacientes de alto riesgo antes.